Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: leflunomide Clear all
Terminated Phase 2 Interventional

An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria

NCT01620268
View directory record Official record
Conditions
Viruria, Viremia
Interventions
Leflunomide and orotic acid
Drug
Lead sponsor
Changzheng-Cinkate
Industry
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 2, 2026, 7:03 AM EDT
Recruiting Phase 1 Interventional

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

NCT05443425
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
Interventions
Cholestyramine, Leflunomide, Steroid Therapy
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 1 Interventional

A Phase I Study of SU101 in Pediatric Patients With Refractory Malignancy

NCT00001573
View directory record Official record
Conditions
Glioma, Sarcoma
Interventions
SU101
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 7:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis

NCT05782335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 2 Interventional

Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse

NCT00003775
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
leflunomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Sep 2, 2026, 7:03 AM EDT
Active, not recruiting Phase 1 Interventional

Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease

NCT04212416
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease
Interventions
Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy

NCT04532372
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Leflunomide, Placebo Administration
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Leflunomide 20 mg Tablets Under Fasting Conditions

NCT00834418
View directory record Official record
Conditions
Healthy
Interventions
Leflunomide 20 mg Tablets, ARAVA™ 20 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 4 Interventional Results available

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

NCT01313208
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
etanercept, Placebo, DMARD Therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 2, 2026, 7:03 AM EDT
Recruiting Phase 1 Interventional

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

NCT06454383
View directory record Official record
Conditions
Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Biospecimen Collection, Cholestyramine, Computed Tomography, Diagnostic Imaging, Gemcitabine, Leflunomide, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 2, 2026, 7:03 AM EDT
Recruiting Phase 3 Interventional

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

NCT03414502
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Active, not recruiting Early Phase 1 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

NCT04370483
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Leflunomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Active, not recruiting Phase 2 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Cholestyramine, Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Recruiting Phase 1 Interventional

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

NCT04997993
View directory record Official record
Conditions
PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Interventions
Leflunomide
Drug
Lead sponsor
Deborah Doroshow
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Withdrawn Phase 2 Interventional

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

NCT00230035
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 1Phase 2 Interventional

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

NCT03709446
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer
Interventions
Leflunomide
Drug
Lead sponsor
Joseph Sparano
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 7:03 AM EDT
Withdrawn Phase 2 Interventional

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

NCT03952832
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Leflunomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 2 Interventional

Leflunomide to Treat Uveitis

NCT00001863
View directory record Official record
Conditions
Uveitis
Interventions
Leflunomide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 7:03 AM EDT
Terminated Phase 1 Interventional

Leflunomide in Mild COVID-19 Patients

NCT04361214
View directory record Official record
Conditions
COVID-19
Interventions
Leflunomide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 2Phase 3 Interventional

Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer

NCT00004071
View directory record Official record
Conditions
Prostate Cancer
Interventions
leflunomide, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
3
States / cities
Boca Raton, Florida • Fort Myers, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 2, 2026, 7:03 AM EDT
Completed Phase 3 Interventional Results available

Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis

NCT00579878
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate-Sulfasalazine-Hydroxychloroquine, Leflunomide-Sulfasalazine-Hydroxychloroquine
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 2, 2026, 7:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 2, 2026, 7:03 AM EDT